Dipharma acquires LogixX Pharma
SourcingClub was not involved in this transaction.
Dipharma, a Swiss specialty pharmaceutical company focused on rare diseases, acquires the British LogixX Pharma Holding Group. LogixX supplies medicines for rare and metabolic diseases to the NHS and homecare providers and has been Dipharma's UK partner for almost ten years. The fertility business is excluded from the transaction.
Manufacturing ChemistWho was involved.
- Buyer
- Dipharma
- Target
- LogixX Pharma
- Type
- Strategic
- Sector
- Healthcare & Medtech
- Country
United Kingdom- First reported
- 06/11/2026
- Source
- Manufacturing Chemist
Deal-Radar no. 46-007 · added in Week 46/2026, first reported on 06/11/2026 · publicly reported, no guarantee · SourcingClub was not involved in this transaction. Report an error · Method
Valuation in this industry.
5.9 to 10.0times EBITDA
- 5.9x to 7.6xRevenue under €5m
- 7.0x to 9.0x€5m to €50m
- 8.2x to 10.0xover €50m
Market range for Healthcare & Medical Technology, not the price of this deal. Data basis: DUB KMU-Multiples, Q3/2026; preparation: SourcingClub.
Multiples by size class for Healthcare & Medical Technology 41 deals in this industry on the radar
November 2026 on the Deal-Radar.
48 of 109 deals so far are of the type Strategic.
- Strategic48
- Add-on16
- Carve-out14
- Funding round14
- Insolvency8
- Buy-out4
- Minority stake3
- Merger1
- Secondary1
New deals every morning. By email on Mondays.
All deals of the previous week in one email, with source and adviser.